BeOne Medicines

Adiós, Madrid. As #ESMO26 comes to a close, we’re reflecting on a week that brought together innovative thinking, new milestones, and a global community united by one of the most complex challenges in medicine – stopping cancer. Thank you to everyone who visited our booth, joined our sessions and connected with our team. Discover how we’re changing the game in solid tumor oncology: https://bit.ly/4z5cT0g #TeamBeOne

We’re catching up with #TeamBeOne in the moment to hear what’s emerging from #ESMO26 this year. Hear their takes on the science catching attention and what it could mean for the field – and for patients. Discover how we're changing the game in solid tumor oncology: https://bit.ly/4z5cT0g #BeOneAgainstCancer #FromFloorToFeed

¡Hola, Madrid! Just 1 day to go until BeOne kicks off #ESMO26 alongside the global oncology community. We look forward to spotlighting the momentum across our rapidly advancing solid tumor pipeline and pursuing new possibilities in areas where progress has been difficult to achieve. If you’re attending, visit us at booth #8026 in Hall 8. Discover how we’re working to change the game in solid tumor oncology: https://lnkd.in/eNviUaGr #TeamBeOne #BeOneAgainstCancer

For many cancers, the past decade has brought remarkable progress. For hepatocellular carcinoma (HCC), the story has been more complicated. Its unique tumor environment, combined with underlying liver damage in many patients, creates a complex scientific challenge. At BeOne, we believe changing the outlook starts with understanding what makes HCC different and pursuing science designed to address the challenges of this disease. As new evidence emerges at #ESMO2026, we explore why HCC has resisted advances, and what it could take to move progress forward for patients. Read the full story: https://lnkd.in/euuKx_qT #BeOneAgainstCancer #LiverCancer

#News for #Investors and #Media: This year at #ESMO26, we’re presenting 11 abstracts, 9 posters, and 2 oral presentations, with data demonstrating the rapid advancement of our investigational solid tumor pipeline. We’re working to change the game in solid tumor oncology, with proof-of-concept programs advancing simultaneously across our strategically focused disease areas. Across breast, gynecological, liver, lung, and gastrointestinal cancers, we’re reinforcing the breadth of our science, the scale of our oncology pipeline, and how we show up for patients by continuing to challenge what’s possible. Stay tuned for more. Explore the data here: https://lnkd.in/eX8Zbeud #BeOneInnovator

The treatment landscape for chronic lymphocytic leukemia (CLL) has shifted in fundamental ways, and the opportunity now is to keep that progress moving forward. At BeOne, we’re committed to building evidence that is deep and broad enough to support confident treatment decisions across the full range of patients with CLL. We’re helping move that progress forward. Read more: https://lnkd.in/eyZTUiM7 #CLL #BeOneAgainstCancer